C57BL/6NCya-Cdk12em1flox/Cya
Common Name:
Cdk12-flox
Product ID:
S-CKO-14426
Background:
C57BL/6NCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Cdk12-flox
Strain ID
CKOCMP-69131-Cdk12-B6N-VA
Gene Name
Product ID
S-CKO-14426
Gene Alias
1810022J16Rik; Crk7; Crkrs; D11Ertd752e; Pksc
Background
C57BL/6NCya
NCBI ID
Modification
Conditional knockout
Chromosome
11
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6NCya-Cdk12em1flox/Cya mice (Catalog S-CKO-14426) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000107538
NCBI RefSeq
NM_001109626
Target Region
Exon 4
Size of Effective Region
~1.8 kb
Detailed Document
Overview of Gene Research
Cyclin-dependent kinase 12 (Cdk12) is a member of the CDK family, which is crucial for various cellular processes. It engages in transcription, post-transcriptional modification, cell cycle, translation, and cellular proliferation. Cdk12 also regulates the expression of cancer-related genes involved in the DNA-damage response (DDR) and replication, maintaining genomic stability [1,3,4,5].
In prostate cancer, biallelic loss of Cdk12 defines a metastatic castration-resistant prostate cancer (mCRPC) subtype. Ablation of Cdk12 in murine prostate epithelium can induce preneoplastic lesions with lymphocytic infiltration. Cdk12 inactivation mediates genomic instability by inducing transcription-replication conflicts. Moreover, Cdk12-mutant organoids and patient-derived xenografts are sensitive to inhibition or degradation of the paralog kinase, Cdk13 [2,6].
In conclusion, Cdk12 is essential for multiple cellular functions, especially in maintaining genomic stability through regulating DDR and replication-related genes. Studies using gene knockout models in mice have revealed its role in prostate cancer progression, highlighting its potential as a therapeutic target for this disease.
References：
1. Emadi, Fatemeh, Teo, Theodosia, Rahaman, Muhammed H, Wang, Shudong. 2020. CDK12: a potential therapeutic target in cancer. In Drug discovery today, 25, 2257-2267. doi:10.1016/j.drudis.2020.09.035. https://pubmed.ncbi.nlm.nih.gov/33038524/
2. Wu, Yi-Mi, Cieślik, Marcin, Lonigro, Robert J, Robinson, Dan R, Chinnaiyan, Arul M. . Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. In Cell, 173, 1770-1782.e14. doi:10.1016/j.cell.2018.04.034. https://pubmed.ncbi.nlm.nih.gov/29906450/
3. Liu, Hui, Liu, Kangdong, Dong, Zigang. 2020. Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery. In Cancer research, 81, 18-26. doi:10.1158/0008-5472.CAN-20-2245. https://pubmed.ncbi.nlm.nih.gov/32958547/
4. Liang, Shujing, Hu, Lifang, Wu, Zixiang, Xu, Xia, Qian, Airong. 2020. CDK12: A Potent Target and Biomarker for Human Cancer Therapy. In Cells, 9, . doi:10.3390/cells9061483. https://pubmed.ncbi.nlm.nih.gov/32570740/
5. Yan, Zhijia, Du, Yongli, Zhang, Haibin, Dong, Ning, He, Fang. 2023. Research progress of anticancer drugs targeting CDK12. In RSC medicinal chemistry, 14, 1629-1644. doi:10.1039/d3md00004d. https://pubmed.ncbi.nlm.nih.gov/37731700/
6. Tien, Jean Ching-Yi, Luo, Jie, Chang, Yu, Ding, Ke, Chinnaiyan, Arul M. 2024. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. In Cell reports. Medicine, 5, 101758. doi:10.1016/j.xcrm.2024.101758. https://pubmed.ncbi.nlm.nih.gov/39368479/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen